Glucagon Injection Sales -- $20.6 million, down 25% year over year in Q2 2025, primarily due to competition and a market shift to ready-to-use products such as Baqsimi. Lidocaine Sales -- $15 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback